

POSTER PRESENTATION

Open Access

Alström syndrome: a paradigm for diffuse fibrosis and clinical progression

Nicola C Edwards^{1*}, William E Moody², Emma Springthorpe³, Peter Weale⁴, Richard Paisey⁵, Tarekgn Geberhiwot⁶, Richard Steeds⁷

From 16th Annual SCMR Scientific Sessions
San Francisco, CA, USA. 31 January - 3 February 2013

Background


Alström syndrome (ALMS) is a rare autosomal recessive genetic disorder characterised by progressive endocrine disarray, sensorineural deficit, cardiac, renal, and hepatic abnormalities. Idiopathic infantile dilated cardiomyopathy (CMP) is common, presenting acutely in 45% of individuals and recurs or develops de novo in 65% of adolescents with high rates of morbidity and mortality. Myocardial fibrosis has been demonstrated at post-mortem and on MRI with patchy diffuse late gadolinium enhancement (LE) in an older cohort of ALMS patients. We hypothesise that subclinical diffuse fibrosis in young patients with ALMS precedes any change in conventional parameters of ventricular function or overt scarring on LE.

Methods

Thirteen patients (mean age 27 +/- 11 years, 77% male, prevalence infantile CM 15%) from the National Specialist Commissioning Group for Alström Syndrome, Birmingham, UK and matched age and gender controls were prospectively assessed with 2D echocardiography and cardiac MRI (1.5T). Late gadolinium enhancement images were acquired 5-7 minutes after contrast. Myocardial extracellular volume (ECV) was assessed using T1-mapping pre and 15 minutes post gadolinium (0.1mmol/Kg) using a modified look-locker inversion recovery sequence (MOLLI) (Figures 1 & 2). Myocardial T1 was measured in the basal and mid septum avoiding areas of LE.

Results

Septal myocardial ECV was increased in female ALMS compared to male ALMS (0.27 +/- 0.02 vs. 0.31 +/- 0.02, $p < 0.05$). Septal myocardial ECV was increased in ALMS compared to controls (0.26 +/- 0.02 vs. 0.29 +/- 0.03, $p < 0.05$). Three male older ALMS patients (mean 43 +/- 5 years vs. 27 +/- 10 years) all without a history of infantile CMP, had patchy diffuse LE in non-coronary artery territories with an increased ECV compared to remote "normal" myocardium (ECV 0.41 +/- 0.08 vs. 0.27 +/- 0.03, $p < 0.05$). There were no differences in mean LV mass, LV ejection fraction or LA volume between ALMS and controls. Increased septal myocardial ECV correlated with a reduction in lateral and



¹Cardiovascular Medicine, University of Birmingham & Queen Elizabeth Hospital Birmingham, Birmingham, UK
Full list of author information is available at the end of the article




Figure 2 MOLLI 15 minutes after contrast with the regions of interest drawn in the basal and mid septum and descending aorta

septal TDI systolic velocities ($r = -0.82$, $p < 0.05$, $r = -0.81$, $p < 0.05$). NT-BNP was not correlated with septal ECV but was increased in patients with LGE (median 178 pmol/L vs. 44 pmol/L).

Conclusions

Patients with ALMS demonstrate a spectrum of myocardial fibrosis, which correlates with reduced longitudinal contractility before changes in conventional markers of LV structure and function. This precedes a clinically significant increase in BNP that appears with overt LE and suggests that increased ECV may be a target for early modification of pharmacological therapy.

Funding

National Commissioning Group

Author details

¹Cardiovascular Medicine, University of Birmingham & Queen Elizabeth Hospital Birmingham, Birmingham, UK. ²Cardiovascular Medicine, University of Birmingham & Queen Elizabeth Hospital Birmingham, Birmingham, UK. ³Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. ⁴Applications Specialist, Siemens Healthcare UK, Camberley, UK. ⁵Endocrinology, Torbay Hospital, Torquay, UK. ⁶Endocrinology, University of Birmingham & Queen Elizabeth Hospital Birmingham, Birmingham, UK. ⁷Cardiology, University of Birmingham & Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Published: 30 January 2013

doi:10.1186/1532-429X-15-S1-P159

Cite this article as: Edwards *et al.*: Alström syndrome: a paradigm for diffuse fibrosis and clinical progression. *Journal of Cardiovascular Magnetic Resonance* 2013 **15**(Suppl 1):P159.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 **BioMed Central**